A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Active, not recruiting · Phase 1 · NCT06544655
Conditions: Advanced Solid Tumors
At a glance
- Research payments reported, 2025
- $8,016
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 213
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986484 (drug), Nivolumab (biological), Oxaliplatin (drug), Capecitabine (drug), Fluorouracil (drug), Calcium folinate (drug)
- Dates
- Started 2024-10-10; completion 2027-10-14
- Results posted
- Not yet
The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).
From ClinicalTrials.gov, last updated 2026-04-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $8,016 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anthony B. El-khoueiry, M.D. Medical Oncology · Los Angeles, CA
- David Sommerhalder Hematology & Oncology · San Antonio, TX
- Aaron P. Scott, MD Emergency Medicine · Pullman, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Usc Norris Comprehensive Cancer Center $2,960
- The University of Arizona Cancer Center - North $2,561
- Next Oncology $2,495
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.